View Older Stories

Apr 15, 2026 08:31AM Allogene publishes preclinical data for dual-targeted autoimmune CAR T

Apr 14, 2026 10:44AM Increasing unusual call option volume: ALLO CORN CNK ALMU ADMA JBL SPIR OGN REPL ORBS LWLG CANE RVMD

Apr 14, 2026 06:47AM Allogene (ALLO) PT Raised to $12 at H.C. Wainwright

Apr 14, 2026 06:12AM Allogene (ALLO) PT Raised to $3.85 at Bernstein SocGen Group

Apr 13, 2026 04:44PM Allogene (ALLO) PT Raised to $8 at Citizens

Apr 13, 2026 12:04PM Oppenheimer on Allogene (ALLO): 'data represents strong early validation of the ALPHA3 strategy'

Apr 13, 2026 11:13AM Jefferies on Allogene (ALLO): expecting strong stock momentum into Cema-cel interim/prelim EFS readouts

Apr 13, 2026 08:50AM Allogene (ALLO) PT Raised to $9 at Baird

Apr 13, 2026 07:31AM Allogene reports 58% disease clearance rate in lymphoma trial

Apr 13, 2026 07:27AM Allogene Therapeutics (ALLO) Halted, News Pending

Apr 10, 2026 01:56AM Jefferies Assumes Allogene (ALLO) at Buy

Mar 16, 2026 04:47AM Citizens on Allogene (ALLO): 'We View Shares as an Attractive Investment Opportunity'

Mar 12, 2026 04:27PM Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 6c

Jan 9, 2026 02:35AM Citizens Upgrades Allogene (ALLO) to Market Outperform

Jan 8, 2026 08:31AM Allogene outlines 2026 clinical milestones for CAR-T therapies

Jan 7, 2026 01:09AM UBS Starts Allogene (ALLO) at Buy

Dec 15, 2025 05:40PM Allogene retains control of cancer therapy after arbitration ruling

Nov 6, 2025 05:04PM Allogene Therapeutics, Inc. (ALLO) Tops Q3 EPS by 3c

Nov 3, 2025 09:04AM Allogene to present ALPHA3 trial data at ASH annual meeting

Oct 10, 2025 03:12AM JPMorgan Downgrades Allogene (ALLO) to Underweight

Aug 20, 2025 04:12AM Citizens JMP Reiterates Market Perform Rating on Allogene (ALLO)

Aug 13, 2025 06:41PM Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Aug 13, 2025 06:41PM Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Aug 4, 2025 05:31AM Citizens JMP Reiterates Market Perform Rating on Allogene (ALLO)

Aug 1, 2025 12:44PM Allogene (ALLO) PT Lowered to $7 at Oppenheimer

Aug 1, 2025 08:31AM Allogene drops experimental drug from lymphoma trial after patient death

Jun 2, 2025 04:54PM Citi Reiterates Buy Rating on Allogene (ALLO)

Jun 2, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Allogene (ALLO)

May 30, 2025 10:00AM Bernstein flags 14 biotechs exploring strategic options, possible M&A

May 22, 2025 05:21PM Allogene Therapeutics (ALLO) announces publication of abstracts on ALLO-316

May 14, 2025 03:13AM Citizens JMP Downgrades Allogene (ALLO) to Market Perform

Apr 7, 2025 08:31AM Allogene Therapeutics (ALLO) Granted Three FDA Fast Track Designations for ALLO-329,

Mar 19, 2025 06:39AM Allogene (ALLO) PT Lowered to $8 at H.C. Wainwright

Mar 14, 2025 10:06AM Citi Reiterates Buy Rating on Allogene (ALLO), PT $8

Mar 14, 2025 03:06AM Citizens JMP Upgrades Allogene (ALLO) to Market Outperform

Mar 13, 2025 04:04PM Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 4c

Feb 25, 2025 04:11PM Allogene Therapeutics (ALLO) Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 13, 2025 04:30PM Allogene Therapeutics (ALLO) Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials

Jan 28, 2025 08:31AM Allogene Therapeutics (ALLO) Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel

Nov 18, 2024 08:37AM Allogene Therapeutics (ALLO) Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergenc

Nov 14, 2024 07:16AM Allogene (ALLO) PT Lowered to $9 at Piper Sandler

Nov 11, 2024 08:36AM H.C. Wainwright Reiterates Buy Rating on Allogene (ALLO)

Nov 7, 2024 04:50PM Allogene Therapeutics, Inc. (ALLO) Tops Q3 EPS by 1c

Nov 7, 2024 10:00AM Allogene Therapeutics (ALLO) Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316

Oct 30, 2024 08:14AM H.C. Wainwright Reiterates Buy Rating on Allogene (ALLO)

Oct 29, 2024 08:30AM Allogene Therapeutics (ALLO) Receives FDA Regenerative Medicine Advanced Therapy Designation for ALLO-316

Oct 22, 2024 04:06PM Artiva Biotherapeutics (ARTV) Appoints Alison Moore to its Board

Oct 17, 2024 06:44AM JPMorgan on Kyverna Therapeutics Inc (KYTX): 'armed with compelling clinical evidence to-date'

Sep 26, 2024 08:33AM Allogene Therapeutics (ALLO) to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases

View Older Stories